TLC-388 HCl

N/A

Report date: 2023/12/01 20:06:44
NME

Base Information

Drug NameTLC-388 HCl
Drug Alias NameLipotecanTLC-388TLC-388 HCl
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAngiogenesis inhibitorsDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsSolid tumoursVenous ThrombosisLiver Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanMainland China
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaIND
Originator CompaniesTaiwan Liposome Company Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTaiwan Liposome Company LtdAlcami Carolinas CorpAaipharma Services Corp +[5] 
Inactive CompaniesNational Health Research Institutes
Active IndicationsLiver NeoplasmsNeuroendocrine Tumors
Inactive IndicationsSolid tumoursVenous ThrombosisCarcinoma, Renal Cell +[5] 

Other Information

ATC CodeN/A
Related LinksN/A